- The two studies of AZD7442 will enroll ~6,000 adults for the prevention of COVID-19 in and outside the US, expected to begin in next wk. with additional trials enrolling ~4,000 adults for the treatment of SARS-CoV-2 infections.
- The first study will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12mos. in ~5,000 participants while the second trial will assess post-exposure prophylaxis and pre-emptive treatment in ~1,100 participants
- AstraZeneca has received ~$486M from US Govt. and plans to supply ~100,000 doses and can acquire other 1M doses. AZD7442 is a combination of 2 LAABs derived from convalescent patients after SARS-CoV-2 infection
Click here to read full press release/ article | Ref: AstraZeneca | Image: Medical Dialogues